These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 21867423

  • 1. Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.
    Greene RJ, Tu H, Gibbs JP, Greg Slatter J.
    Xenobiotica; 2011 Nov; 41(11):945-57. PubMed ID: 21867423
    [Abstract] [Full Text] [Related]

  • 2. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D.
    Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
    [Abstract] [Full Text] [Related]

  • 3. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
    He H, Tran P, Yin H, Smith H, Flood D, Kramp R, Filipeck R, Fischer V, Howard D.
    Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
    [Abstract] [Full Text] [Related]

  • 4. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.
    Diez-Torrubia A, García-Aparicio C, Cabrera S, De Meester I, Balzarini J, Camarasa MJ, Velázquez S.
    J Med Chem; 2010 Jan 28; 53(2):559-72. PubMed ID: 20000418
    [Abstract] [Full Text] [Related]

  • 5. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
    Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, Shipkova P, Marcinkeviciene J, Hamann L, Kirby MS.
    BMC Pharmacol; 2012 Apr 04; 12():2. PubMed ID: 22475049
    [Abstract] [Full Text] [Related]

  • 6. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.
    Diez-Torrubia A, Balzarini J, Andrei G, Snoeck R, De Meester I, Camarasa MJ, Velázquez S.
    J Med Chem; 2011 Mar 24; 54(6):1927-42. PubMed ID: 21332170
    [Abstract] [Full Text] [Related]

  • 7. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
    Namoto K, Sirockin F, Ostermann N, Gessier F, Flohr S, Sedrani R, Gerhartz B, Trappe J, Hassiepen U, Duttaroy A, Ferreira S, Sutton JM, Clark DE, Fenton G, Beswick M, Baeschlin DK.
    Bioorg Med Chem Lett; 2014 Feb 01; 24(3):731-6. PubMed ID: 24439847
    [Abstract] [Full Text] [Related]

  • 8. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.
    Rosmaninho-Salgado J, Marques AP, Estrada M, Santana M, Cortez V, Grouzmann E, Cavadas C.
    Peptides; 2012 Sep 01; 37(1):49-54. PubMed ID: 22819773
    [Abstract] [Full Text] [Related]

  • 9. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219
    [Abstract] [Full Text] [Related]

  • 10. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D.
    J Clin Pharmacol; 2008 Jan 25; 48(1):85-95. PubMed ID: 17986525
    [Abstract] [Full Text] [Related]

  • 11. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.
    Diez-Torrubia A, Cabrera S, de Castro S, García-Aparicio C, Mulder G, De Meester I, Camarasa MJ, Balzarini J, Velázquez S.
    Eur J Med Chem; 2013 Jan 25; 70():456-68. PubMed ID: 24185376
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug 25; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
    Ayalasomayajula SP, Dole K, He YL, Ligueros-Saylan M, Wang Y, Campestrini J, Humbert H, Sunkara G.
    Curr Med Res Opin; 2007 Dec 25; 23(12):2913-20. PubMed ID: 17931461
    [Abstract] [Full Text] [Related]

  • 14. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
    Tanaka-Amino K, Matsumoto K, Hatakeyama Y, Takakura S, Mutoh S.
    Acta Diabetol; 2010 Mar 25; 47(1):43-8. PubMed ID: 19238312
    [Abstract] [Full Text] [Related]

  • 15. Crystal structure study and investigation of solid-state cyclization for AMG 222, a channel hydrate.
    Kiang YH, Nagapudi K, Liu J, Staples RJ, Jona J.
    Int J Pharm; 2013 Jan 30; 441(1-2):299-306. PubMed ID: 23182974
    [Abstract] [Full Text] [Related]

  • 16. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
    Tonn GR, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, Floren LC, Kersey K, Berry K, Marcus AP, Wang X, Van Lengerich B, Medina JC, Pearson PG, Wong BK.
    Drug Metab Dispos; 2009 Mar 30; 37(3):502-13. PubMed ID: 19088267
    [Abstract] [Full Text] [Related]

  • 17. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin.
    Asakura M, Nakano M, Hayashida K, Fujii H, Nakajima M, Atsuda K, Itoh T, Fujiwara R.
    Drug Metab Pharmacokinet; 2014 Mar 30; 29(6):463-9. PubMed ID: 25008847
    [Abstract] [Full Text] [Related]

  • 18. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.
    Jost MM, Lamerz J, Tammen H, Menzel C, De Meester I, Lambeir AM, Augustyns K, Scharpé S, Zucht HD, Rose H, Jürgens M, Schulz-Knappe P, Budde P.
    Biochem Pharmacol; 2009 Jan 15; 77(2):228-37. PubMed ID: 18940185
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
    Brandt I, Joossens J, Chen X, Maes MB, Scharpé S, De Meester I, Lambeir AM.
    Biochem Pharmacol; 2005 Jul 01; 70(1):134-43. PubMed ID: 15907807
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
    Bianchi R, Cervellini I, Porretta-Serapiglia C, Oggioni N, Burkey B, Ghezzi P, Cavaletti G, Lauria G.
    J Pharmacol Exp Ther; 2012 Jan 01; 340(1):64-72. PubMed ID: 21984837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.